L

Lavipharm SA
ATHEX:LAVI

Watchlist Manager
Lavipharm SA
ATHEX:LAVI
Watchlist
Price: 1.03 EUR 4.67% Market Closed
Market Cap: €173.8m

Operating Margin

11.5%
Current
Improving
by 1.3%
vs 3-y average of 10.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
11.5%
=
Operating Income
€6.1m
/
Revenue
€53.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
11.5%
=
Operating Income
€6.1m
/
Revenue
€53.3m

Peer Comparison

Country Company Market Cap Operating
Margin
GR
Lavipharm SA
ATHEX:LAVI
166m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
5.1B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

In line with most companies in Greece
Percentile
49th
Based on 330 companies
49th percentile
11.5%
Low
-1 006.6% — 4.1%
Typical Range
4.1% — 20.3%
High
20.3% — 139.8%
Distribution Statistics
Greece
Min -1 006.6%
30th Percentile 4.1%
Median 11.9%
70th Percentile 20.3%
Max 139.8%

Lavipharm SA
Glance View

Market Cap
173.8m EUR
Industry
Pharmaceuticals

Lavipharm SA engages in the manufacture and import of pharmaceuticals and veterinary products. The company is headquartered in Athina, Attiki. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. The company is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.

LAVI Intrinsic Value
0.66 EUR
Overvaluation 36%
Intrinsic Value
Price
L
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
11.5%
=
Operating Income
€6.1m
/
Revenue
€53.3m
What is Lavipharm SA's current Operating Margin?

The current Operating Margin for Lavipharm SA is 11.5%, which is above its 3-year median of 10.2%.

How has Operating Margin changed over time?

Over the last 3 years, Lavipharm SA’s Operating Margin has increased from 8.6% to 11.5%. During this period, it reached a low of 8.6% on May 30, 2022 and a high of 12.6% on Jun 30, 2024.

Back to Top